Skip to content

13F-HR filed by Euclidean Capital LLC

Euclidean Capital LLC filed this 13F-HR for the quarter ended 2026-03-31, filed 2026-05-15, with 10 holding rows worth $392,310,878.

Accession
0001012975-26-000442
Filed
2026-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2026

A holdings report, 10 entries on the cover page, a total value of $392,310,878 stated on the cover page (in dollars after the unit check, H1), rows summing to $392,310,878 with VALUE read as dollars as filed, 13F file number 028-20777. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
Vanguard FTSE All-World ex-US ETF922042775SHS3,243,484$243,585,648dollars as filed
Vanguard Value ETF922908744SHS520,000$102,024,000dollars as filed
ISHARES TR46429B598MSCI INDIA ETF369,600$17,312,064dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM989,410$12,535,825dollars as filed
FOGHORN THERAPEUTICS INC344174107COMMON STOCK1,573,761$7,522,578dollars as filed
PMV PHARMACEUTICALS INC69353Y103COM2,627,643$3,258,277dollars as filed
ALECTOR INC014442107COMMON STOCK1,307,858$2,811,895dollars as filed
SURROZEN INC86889P208COMMON STOCK87,696$2,554,584dollars as filed
TENAYA THERAPEUTICS INC87990A106COM1,015,705$703,274dollars as filed
SURROZEN INC86889P117*W EXP 08/01/203170,833$2,733dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-26-000442this filing2026-05-15acceptance time not in the bulk data set